ESTROGEN AND ANDROGEN RECEPTOR-MEDIATED STIMULATION AND INHIBITION OFPROLIFERATION BY ANDROST-5-ENE-3-BETA,17-BETA-DIOL IN HUMAN MAMMARY-CANCER CELLS

Citation
R. Hackenberg et al., ESTROGEN AND ANDROGEN RECEPTOR-MEDIATED STIMULATION AND INHIBITION OFPROLIFERATION BY ANDROST-5-ENE-3-BETA,17-BETA-DIOL IN HUMAN MAMMARY-CANCER CELLS, Journal of steroid biochemistry and molecular biology, 46(5), 1993, pp. 597-603
Citations number
30
Categorie Soggetti
Biology,"Endocrynology & Metabolism
ISSN journal
09600760
Volume
46
Issue
5
Year of publication
1993
Pages
597 - 603
Database
ISI
SICI code
0960-0760(1993)46:5<597:EAARSA>2.0.ZU;2-2
Abstract
Androst-5-ene-3beta,17beta-diol (ADIOL) and 5alpha-androstane-3beta,17 beta-diol (5alphaA), which are metabolites of dehydroepiandrosterone a nd dihydrotestosterone, are known to have estrogenic properties. This study reevaluates the estrogenic effects of ADIOL and 5alphaA in MCF-7 cells and demonstrates additionally androgen-like inhibitory properti es of these compounds in human hormone-dependent mammary cancer cells. ADIOL and 5alphaA (10-100 nM) stimulate the proliferation of estrogen -sensitive MCF-7 cells. Binding assays with the estrogen receptor and inhibition of stimulation with the antiestrogen tamoxifen support the involvement of the estrogen receptor. On the other hand, the mammary c ancer cell line MFM-223 is strongly inhibited by ADIOL and 5alphaA in the same concentration range. This cell line is androgen receptor posi tive and is inhibited by androgens, but unresponsive to estrogens and progestins. The inhibitory effects of ADIOL and 5alphaA in MFM-223 cel ls are mediated by the androgen receptor as demonstrated by receptor s tudies and competition experiments with hormone antagonists. ADIOL and 5alphaA thus possess estrogen- and androgen-like properties and can s timulate or inhibit proliferation of human mammary cancer cells. The r eactions of mammary cancer cells to these steroids depend on the recep tor content and the growth properties of the individual cell line.